Synonyms: BIIB-059 | BIIB059
Compound class:
Antibody
Comment: Litifilimab (BIIB059) is a fully humanized IgG1, CLEC4C (blood dendritic cell antigen 2, BDCA2) targeting monoclonal antibody. It is being evaluated for ability to reduce release of disease-driving interferons (principally IFN-α) in SLE/CLE. BIIB059 was developed by Biogen, based on prior evidence of target engagement and SLE-applicable immunomodulatory efficacy of a humanized mAb against BDCA2 named 24F4A [3].
|
Classification ![]() |
|
Compound class | Antibody |
International Nonproprietary Names ![]() |
|
INN number | INN |
11943 | litifilimab |
Synonyms ![]() |
BIIB-059 | BIIB059 |
Database Links ![]() |
|
GtoPdb PubChem SID | 434122182 |
Search PubMed clinical trials | litifilimab |
Search PubMed titles | litifilimab |
Search PubMed titles/abstracts | litifilimab |